December 1, 2016
Sustained virologic response 12 weeks after elbasvir/grazoprevir (EBR/GZR, Zepatier) therapy ended (SVR12) reached 93% among HCV genotype 1 and 4 patients in the double-blind, placebo-controlled C-CORAL trial. SVR12 rates did not differ by sex, age or fibrosis stage.
HCV prevalence in the Asia/Pacific region and Russia ranges from 1% to 5%, with genotype 1b accounting for about half of infections. Fixed-dose one-tablet once-daily EBR/GZR is licensed for treatment of genotype 1 and 4 HCV in the United States, the European Union and elsewhere. C-CORAL collaborators conducted this trial to assess EBR/GZR efficacy and safety in Korea, Taiwan, Vietnam, Thailand, Australia and Russia. EBV is an NS5A inhibitor, and GZR is an NS3/4A protease inhibitor.
The phase 3 trial randomized 250 participants to immediate EBR/GZR and 86 to placebo for 12 weeks, followed by unblinding and EBR/GZR for the placebo group. All patients had HCV genotype 1, 4 or 6 and none had HIV; they could have compensated cirrhosis. The primary endpoint was SVR12 in the immediate EBR/GZR arm.
Overall SVR12 in the immediate EBR/GZR arm was 93% and was high for genotype 1a (89%), 1b (99%) and 4 (100%), but not for genotype 6 (63%). Among 13 patients without SVR12 in the genotype 6 arm, three had virologic breakthroughs, three had rebounds and seven had relapses. SVR12 rates were moderately higher in white patients than Asians (98% versus 89%) but did not differ substantially by sex, age over or under 65 years, cirrhosis status or baseline viral load.
Nearly one quarter of genotype 1a and 1b patients had NS5A resistance-associated variants (RAVs) at baseline, as did one of two patients with genotype 4 and 15 of 34 patients (44%) with genotype 6. Among genotype 1a patients, SVR12 rates were lower in patients with than without RAVs (67% versus 95%), but response rates were similar with and without RAVs in the genotype 1b group (97% and 100%) and the genotype 4 group (100% and 100%). In the genotype 6 group, SVR12 rates were 40% with baseline RAVs and 79% without RAVs.
Half of participants in the immediate and deferred EBR/GZR arms had at least one adverse event, and about 20% in each arm had a drug-related adverse event. The two serious adverse events in the immediate arms were not drug related and one participant in the immediate arm stopped treatment because of an adverse event (elevated alanine aminotransferase and bilirubin).
C-CORAL investigators concluded that "a 12-week regimen of EBR/GZR is effective and well-tolerated in [genotype 1] and [genotype 4]-infected, treatment-naive patients in the Asia Pacific/Russia region."
Mark Mascolini writes about HIV and hepatitis virus infection.
Copyright © 2016 Remedy Health Media, LLC. All rights reserved.
|Liver Cancer Risk 60% Lower After SVR in Nationwide Danish Study|
|Spurred by Success of Remote Hepatitis C Care, Program Targets Remote Primary Care|
No comments have been made.
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.
|Separate and Unequal Access Frames Discussion at CROI Panel on U.S. HIV Care Cascade|
|CROI 2018: Highlights and What's Next for Advocates|
|Reported PrEP 'Failure' Most Likely a Lack of Proper Testing and Adherence|
|Injection Drug Use Among People Living With HIV: A Missed Opportunity to Save Lives|
|Statin Use Might Reduce Risk of Cancer in HIV-Positive People|
|Insurers and Pharmas Must Help Fix HIV Drug Pricing System, Advocates Say|